Skip to main content

Table 5 Comparison of cytogenetic abnormalities between MDS and AML patients

From: Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia

 Total 325Total 93p value
Genes mutation total events (mean, %)2.021.780.147#
 TET2164 (50.5%)72 (77.4%)0.000001**
 ASXL162 (19.1%)21 (22.6%)0.4551
 CEBPA56 (17.2%)5 (5.4%)0.0043**
 FLT353 (16.3%)0 (0.0%)0.000**
 DNMT3A44 (13.5%)5 (5.4%)0.030962*
 NRAS39 (12.0%)7 (7.5%)0.2242
 NPM136 (11.1%)1 (1.1%)0.002752
 RUNX125 (7.7%)9 (9.7%)0.536892
 IDH122 (6.8%)0 (0.0%)0.000**
 IDH222 (6.8%)1 (1.1%)0.000628**
 KIT19 (5.8%)0 (0.0%)0.000**
 ETV69 (2.8%)4 (4.3%)0.0417*
 TP539 (2.8%)5 (5.4%)0.217879
 WT18 (2.5%)0 (0.0%)0.000**
 U2AF18 (2.5%)18 (19.4%)0.000**
 PHF68 (2.5%)1 (1.1%)0.417
 EZH27 (2.2%)1 (1.1%)0.503
 TTN7 (2.2%)0 (0.0%)N/A
 SF3B17 (2.2%)5 (5.4%)0.101
 SRSF24 (1.2%)5 (5.4%)0.015
 JAK23 (0.9%)2 (2.2%)0.337
DNA methylation (frequency, %)252 (77.5%)72 (77.4%)0.980646
RNA spliceosome (frequency, %)20 (6.15%)28 (30.1%)0.000**
Chromatin remodelling (frequency, %)69 (21.2%)22 (23.7%)0.617282
Transcriptional deregulation (frequency, %)89 (27.4%)14 (15.1%)0.014963*
Activated signalling (frequency, %)118 (36.3%)10 (10.8%)0.000002**
  1. #Although there was difference, but no statistically significance was observed between two groups
  2. *Statistically difference (p < 0.05) was obseved between two groups
  3. **Statistically singnificant difference (p < 0.01) was obseved between two groups